MedTrace Logo

DNA-based Influenza Vaccine in the Elderly

NCT01587131 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-04-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether FVH1, a DNA-based influenza vaccine, will be safe and generally well tolerated in healthy elderly adult volunteers and will result in greater immunogenicity when used to prime the immune response to a dose of a trivalent inactivated seasonal vaccine.

Conditions

  • Influenza, Human
  • Orthomyxoviridae Infections
  • RNA Virus Infections
  • Virus Diseases
  • Respiratory Tract Infections
  • Respiratory Tract Diseases

Interventions

BIOLOGICAL

FVH1 - a DNA-based influenza vaccine

0.9 mg FVH1 vaccine

Sponsors & Collaborators

Principal Investigators

  • Gary Kobinger, PhD · National Microbiology & University of Manitoba

  • Trina Racine, PhD · National Microbiology Laboratory, Canada

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-08-31
Completion
2015-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01587131 on ClinicalTrials.gov